HIV vaccines - Wyeth

Drug Profile

HIV vaccines - Wyeth

Alternative Names: GENEVAX gag-2962; GENEVAX-HIV

Latest Information Update: 05 Oct 2011

Price : $50

At a glance

  • Originator Wyeth
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 24 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the Viral infections pharmacodynamics section
  • 30 Sep 2005 The HIV Vaccine Trials Network (HVTN) initiates enrolment in the HVTN 063 trial with Wyeth's HIV DNA vaccine in the US and Brazil
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top